SCHEMBL8320542

SCHEMBL8320542

Fc1ccc(-c2cnc3[nH]cc(I)c3c2)cc1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 5/20 0.59
CLK1 P49759 3/20 0.59
DYRK2 Q92630 3/20 0.59
DYRK1B Q9Y463 3/20 0.59
CLK2 P49760 1/20 0.59
CLK4 Q9HAZ1 1/20 0.59
KIT P10721 2/20 0.59
MAP3K11 Q16584 2/20 0.57
CCNT1 O60563 1/20 0.54
CCNA2 P20248 1/20 0.54
CDK2 P24941 1/20 0.54
CDK9 P50750 1/20 0.54
AXL P30530 3/20 0.53
TNIK Q9UKE5 2/20 0.53
CDK8 P49336 1/20 0.53
AAK1 Q2M2I8 1/20 0.52
BRD4 O60885 1/20 0.50
NTRK1 P04629 1/20 0.48
GSK3B P49841 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8941778 0.86 DYRK1A (0.77) DYRK1ACLK1DYRK2DYRK1BCLK2
SCHEMBL12829259 0.84 NTRK1 (0.66) DYRK1ACLK1DYRK2DYRK1BKIT
SCHEMBL20408723 0.84 KIT (0.59) DYRK1ACLK1DYRK2DYRK1BKIT
SCHEMBL1800807 0.84 AXL (0.73) KITMAP3K11AXLTNIKCDK8
SCHEMBL13746314 0.84 DYRK1A (0.49) DYRK1ACLK1DYRK2DYRK1BCLK2
SCHEMBL8320268 0.81 KIT (0.61) DYRK1ACLK1DYRK2DYRK1BKIT
SCHEMBL8320989 0.81 AXL (0.83) DYRK1ACLK1DYRK2DYRK1BCLK2
SCHEMBL8320227 0.81 KIT (0.67) DYRK1AKITMAP3K11CCNT1CCNA2
SCHEMBL1487612 0.81 MAPK8 (0.67) DYRK1ACLK1DYRK2DYRK1BKIT
SCHEMBL1880862 0.80 BRD4 (0.47) DYRK1ACLK1DYRK2DYRK1BCLK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215771-A1 JNK INHIBITORS GRACZYK PIOTR 2009-08-27 US disclosed
US-20090215771-A1 JNK INHIBITORS GRACZYK PIOTR 2009-08-27 US disclosed
US-7432375-B2 JNK inhibitors EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-10-07 US disclosed
US-7432375-B2 JNK inhibitors EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-10-07 US disclosed
WO-2004078756-A2 JNK INHIBITORS EISAI CO., LTD. (JP) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215771-A1 JNK INHIBITORS MAPKAPK2, MAPK1, MAPKAPK3 DYRK1A 1619/4885CLK1 1119/4885DYRK2 1045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.